Azitra (AZTR) Liabilities and Shareholders Equity (2022 - 2026)
Azitra's (AZTR) quarterly Liabilities and Shareholders Equity came in at $12.1 million in Q1 2026, up 105.26% YoY from $5.9 million in Q1 2025, and up 141.31% on a QoQ basis from $5.0 million in Q4 2025.
Azitra (AZTR) Liabilities and Shareholders Equity (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Liabilities and Shareholders Equity data on file, last reported at $12.1 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 105.26% year-over-year to $12.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.4 million (down 5.64% YoY) and the FY2025 annual result came in at $5.0 million, down 31.71% from the prior year.
- Liabilities and Shareholders Equity climbed to $12.1 million in Q1 2026, from $5.0 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $12.1 million in Q1 2026 to a low of $3.9 million in Q2 2024.
- A 5-year average of $6.8 million and a median of $6.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity slumped 60.5% — and 2026, when it surged 105.26%.
- Tracing AZTR's Liabilities and Shareholders Equity over 5 years: stood at $7.2 million in 2022, then dropped by 28.63% to $5.1 million in 2023, then soared by 43.85% to $7.4 million in 2024, then sank by 31.71% to $5.0 million in 2025, then jumped by 141.31% to $12.1 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $12.1 million (Q1 2026), $5.0 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Azitra | 2.53 Mn | 2.53 Mn | - | 8.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.92 Mn |
| Mar 31, 2026 | 12.13 Mn |
| Dec 31, 2025 | 5.03 Mn |
| Sep 30, 2025 | 4.30 Mn |
| Jun 30, 2025 | 3.96 Mn |
| Mar 31, 2025 | 5.91 Mn |
| Dec 31, 2024 | 7.36 Mn |
| Sep 30, 2024 | 9.78 Mn |
| Jun 30, 2024 | 3.88 Mn |
| Mar 31, 2024 | 6.07 Mn |
| Dec 31, 2023 | 5.12 Mn |
| Sep 30, 2023 | 7.49 Mn |
| Jun 30, 2023 | 9.83 Mn |
| Dec 31, 2022 | 7.17 Mn |